Browse > Article

Clinical Findings and Gene Analysis of 3-Methylcrotonyl-CoA Carboxylase Deficiency  

Lee, Seung Eun (Department of Pediatrics, Soonchunhyang University Hospital)
Ahn, Hee Jae (Department of Pediatrics, Soonchunhyang University Hospital)
Lee, Jeongho (Department of Pediatrics, Soonchunhyang University Hospital)
Lee, Dong Hwan (Department of Pediatrics, Soonchunhyang University Hospital)
Publication Information
Journal of The Korean Society of Inherited Metabolic disease / v.15, no.1, 2015 , pp. 1-8 More about this Journal
Abstract
Purpose: 3-methylcrotonyl CoA carboxylase deficiency (3MCCD) is leucine metabolic disorder caused by mutation in MCCC1 or MCCC2 gene. Clinical manifestations are variable, ranging from fatal neonatal onset to asymptomatic individuals. There is no retrospective study of Korean patients undergoing long-term treatment for 3MCCD. We reported this study to find out clinical symptoms and gene analysis of 3MCCD patients. Methods: This study was based on data of patients diagnosed with 3MCCD in Soonchunhyang university hospital between April 2009 and September 2013. We report clinical, enzymatic and mutation data of 3MCCD patients found by newborn screening. Results: In tandem mass spectrometry, 3-OH-isovalerylcarnitine (C5OH) of all patients increased. And all 7 patients were elevated 3-methylcrotonylglycine (3MCG) and 3-hydroxyisovaleric acid (3HIVA) in urine. MCCC mutation was identified in 2 patients and MCCC2 was mutated in 5 patients. We found mutation occurred in 8 different parts of nucleotide and such mutation caused 7 different types of changes in amino acid. All patients are on medication of L-carnitine and L-glycine. 4 patients are taking biotin. And 4 patients are eating leucine free formula. After starting treatment, there were no significant changes of urine 3MCG and 3HIVA levels. Conclusions: According to our data, MCCC2 gene mutation was more common than MCCC1 gene mutation. But the level of 3HIVA or 3MCG in urine has no correlation with phenotype. All patients has no symptoms and are shown normal development.
Keywords
3-methylcrotonyl CoA carboxylase deficiency (3MCCD); Clinical manifestation; Gene analysis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Uematsu M, Sakamoto O, Sugawara N, Kumagai N, Morimoto T, Yamaguchi S, et al. Novel mutations in five Japanese patients with 3-methylcrotonyl-CoA carboxylase deficiency. J Hum Genet 2007;52:1040-3.   DOI
2 Gallardo ME, Desviat LR, Rodrigues JM, Esparza-Gordillo J, Perez-Cerda C, Perez B, et al. The molecular basis of 3-methlcrotonylglycinuria, a disorder of leucine catabolsim. Am J Hum Genet 2001;68:334-6.   DOI
3 Beemer FA, Bartlett K, Duran M, Ghneim HK, Wadman SK, Bruinvis L, et al. Isolated biotinresistant 3-methylcrotonyl-CoA carboxylase deficiency in two sibs. Eur J Pediatr 1982;138:351-4.   DOI
4 Mourmans J, Bakkeren J, de Jong J, Wevers R, van Diggelen OP, Suormala T, et al. Isolated (biotinresistant) 3-methylcrotonyl-CoA carboxylase deficiency: Four sibs devoid of pathology. J Inherit Metab Dis 1995;18:643-5.   DOI
5 Pearson MA, Aleck KA, Heidenreich RA. Benign clinical presentation of 3-methylglycinuria. J Inherit Metab Dis 1995;18:640-1.   DOI
6 Arnold GL, Koeberl DD, Matern D, Barshop B, Braverman N, Burton B, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008,93:363-70.   DOI
7 Oude Luttikhuis HG, Touati G, Rabier D, Williams M, Jakobs C, Saudubray JM. Severe hypoglycaemia in isolated 3-methylcrotonyl-CoA carboxylase deficiency; a rare, severe clinical presentation. J Inherit Metab Dis 2005,28:1136-8.   DOI
8 Arnold GL, Koeberl DD, Matern D, Barshop B, Braverman N, Burton B, et al. A Delphi-based consensus clinical practice protocol for the diagnosis and management of 3-methylcrotonyl CoA carboxylase deficiency. Mol Genet Metab 2008,93:363-70.   DOI
9 Naylor EW, Chace DH. Automated tandem mass spectrometry for mass newborn screening for disorders in fatty acid, organic acid, and amino acid metabolism. J Child Neurol 1999;14:S4-8.   DOI
10 Koeberl DD, Millington DS, Smith WE, Weavil SD, Muenzer J, McCandless SE, et al. Evaluation of 3-methylcrotonyl-CoA carboxylase deficiency detected by tandem mass spectrometry newborn screening. J Inherit Metab Dis 2003;26:25-35.   DOI
11 Roscher AA, Liebl B, Fingerhut R, Olgemoller B. Prospective study of MSMS newborn screening in Bavaria, Germany. J Inherit Metab Dis 2000;23:4.
12 Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, Hoffmann GF. Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 2003;111:1399-406.   DOI
13 Wilcken B, Wiley V, Hammond J, Carpenter K. Screening newborns for inborn errors of metabolism by tandem mass spectrometry. N Engl JMed 2003;348:2304-12.   DOI
14 Holzinger A, Roschinger W, Lagler F, Mayerhofer PU, Lichtner P, Kattenfeld T, et al. Cloning of the human MCCA and MCCB genes and mutations therein reveal the molecular cause of 3-methylcrotonyl-CoA: carboxylase deficiency. Hum Mol Genet 2001;10:1299-306.   DOI
15 Baumgartner MR, Almashanu S, Suormala T, Obie C, Cole RN, Packman S, et al. The molecular basis of human 3-methylcrotonyl-CoA carboxylase deficiency. J Clin Invest 2001;107:495-504.   DOI
16 Bannwart C, Wermuth B, Baumgartner R, Suormala T, Wiesmann UN. Isolated biotin-resistant deficiency of 3-methylcrotonyl-CoA carboxylase presenting as a clinically severe form in a newborn with fatal outcome. J Inherit Metab Dis 1992;15:863-8.   DOI
17 Stadler SC, Polanetz R, Maier EM, Heidenreich SC, Niederer B, Mayerhofer PU, et al. Newborn screening for 3-methylcrotonyl-CoA carboxylase deficiency: population heterogeneity of MCCA and MCCB mutations and impact on risk assessment. Hum Mutat 2006;27:748-59.   DOI
18 Dodelson de Kremer R, Latini A, Suormala T, Baumgartner ER, Larovere L, Civallero G, et al. Leukodystrophy and CSF purine abnormalities associated with isolated 3-methylcrotonyl-CoA carboxylase deficiency. Metabolic Brain Disease 2002;17:13-8.   DOI
19 Baykal T, Huner Gokcay G, Ince Z, Dantas MF, Fowler B, Baumgartner MR, et al. 3-methylcrotonyl-CoA carboxylase deficiency with early onset necrotizing encephalopathy and lethal outcome. J Inherit Metab Dis 2005;28:229-33.   DOI
20 Gibson KM, Bennett MJ, Naylor EW, Morton DH. 3-Methylcrotonyl-coenzyme A carboxylase deficiency in Amish/Mennonite adults identified by detection of increased acylcarnitines in blood spots of their children. J Pediatr 1998,132:519-23.   DOI
21 DantasMF, Suormala T, Randolph A, Coelho D, Fowler B, Valle D, et al. 3-Methylcrotonyl-CoA carboxylase deficiency: mutation analysis in 28 probands, 9 symptomatic and 19 detected by newborn screening. Hum Mutat 2005;26:164.
22 SY Cho, H-D Park, Y-W Lee, C-S Ki, S-Y Lee, YB Sohn, et al. Mutational spectrum in eight Korean patients with 3-methylcrotonyl-CoA carboxylase deficiency. Clin Genet 2012;81:96-8.   DOI
23 Visser G, Suormala T, Smit GP, Reijngoud DJ, Bink-Boelkens MT, Niezen-Koning KE, et al. 3-methylcrotonyl-CoA carboxylase deficiency in an infant with cardiomyopathy, in her brother with developmental delay and in their asymptomatic father. Eur J Pediatr 2000;159:901-4.   DOI
24 Sarah C Grunert, Martin Stucki, Raphael J Morscher, Terttu Suormala, Celine Burer, Patricie Burda, et al. 3-methylcrotonyl-CoA carboxylase deficiency: Clinical, biochemical, enzymatic and molecular studies in 88 individuals.
25 Sweetman L, Williams JC. Branched chain organic acidurias. In In The Metabolic & Molecular Bases of Inherited Disease. 8th edition. Edited by Scriver CR, Beaudet AL, Sly WS, Valle D. New York: McGraw Hill; 2001:2125-63.
26 Eminoglu FT, Ozcelik AA, Okur I, Tumer L, Biberoglu G, Demir E, et al. 3-Methylcrotonyl-CoA carboxylase deficiency: phenotypic variability in a family. J Child Neurol 2009,24:478-81.   DOI